IQVIA Holdings Inc. in 2 stories
The narratives IQV currently appears in, with its side and exposure in each.
Bull side
1 story- GLP-1 Eats Everything
IQV in “GLP-1 Eats Everything”
FadingExposure: not rated yetAppetite suppression as a macro variable.
IQVIA benefits from the large number of obesity, combination-therapy, and cardiometabolic clinical trials requiring outsourced research and data services.
Bear side
1 story- China Becomes Pharma's Global R&D Engine
IQV in “China Becomes Pharma's Global R&D Engine”
FadingExposure: not rated yetWestern drugmakers are licensing clinically validated Chinese molecules rather than relying solely on expensive in-house discovery.
Sponsors sourcing more development work through Chinese networks can constrain growth in higher-cost traditional trial services.